• 1
    Kaplan JE, Hanson D, Dworkin MS et al. Epidemiology of human immunodeficiency virus-associated opportunistic infections in the united states in the era of highly active antiretroviral therapy. Clin Infect Dis2000; 30 (Suppl 1): S5S14.
  • 2
    Castro KG, Ward JW, Slutsker L et al . 1993 revised classification system for hiv infection and expanded surveillance case definition for aids among adolescents and adults. MMWR Recomm Rep1992; 41: 119.
  • 3
    Huang L, Hecht FM, Stansell JD, Montanti R, Hadley WK, Hopewell PC. Suspected pneumocystis carinii pneumonia with a negative induced sputum examination. Is early bronchoscopy useful?. Am J Respir Crit Care Med1995; 151: 18661871.
  • 4
    Russian DA, Kovacs JA. Pneumocystis carinii in africa: An emerging pathogen?Lancet1995; 346: 12421243.
  • 5
    Thomas CF Jr, Limper AH. Pneumocystis pneumonia. N Engl J Med2004; 350: 24872498.
  • 6
    Torres HA, Chemaly RF, Storey R et al. Influence of type of cancer and hematopoietic stem cell transplantation on clinical presentation of pneumocystis jiroveci pneumonia in cancer patients. Eur J Clin Microbiol Infect Dis2006; 25: 382388.
  • 7
    Jules-Elysee KM, Stover DE, Zaman MB, Bernard EM, White DA. Aerosolized pentamidine: effect on diagnosis and presentation of pneumocystis carinii pneumonia. Ann Intern Med1990; 112: 750757.
  • 8
    Fischl MA, Dickinson GM, La Voie L. Safety and efficacy of sulfamethoxazole and trimethoprim chemoprophylaxis for pneumocystis carinii pneumonia in aids. JAMA1988; 259: 11851189.
  • 9
    Skelly M, Hoffman J, Fabbri M, Holzman RS, Clarkson AB Jr, Merali S. S-adenosylmethionine concentrations in diagnosis of pneumocystis carinii pneumonia. Lancet2003; 361: 12671268.
  • 10
    Vassallo R, Standing JE, Limper AH. Isolated pneumocystis carinii cell wall glucan provokes lower respiratory tract inflammatory responses. J Immunol2000; 164: 37553763.
  • 11
    Arends LR, Hamza TH, van Houwelingen JC, Heijenbrok-Kal MH, Hunink MG, Stijnen T. Bivariate random effects meta-analysis of roc curves. Med Decis Making2008; 28: 621638.
  • 12
    Reitsma JB, Glas AS, Rutjes AW, Scholten RJ, Bossuyt PM, Zwinderman AH. Bivariate analysis of sensitivity and specificity produces informative summary measures in diagnostic reviews. J Clin Epidemiol2005; 58: 982990.
  • 13
    Glas AS, Lijmer JG, Prins MH, Bonsel GJ, Bossuyt PM. The diagnostic odds ratio: a single indicator of test performance. J Clin Epidemiol2003; 56: 11291135.
  • 14
    Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med2002; 21: 15391558.
  • 15
    Macaskill P, Gatsonis C, Deeks JJ, Harbord RM, Takwoingi Y. Chapter 10: analysing and presenting results. In: Deeks JJ, Bossuyt PM, Gatsonis C, eds, Cochrane handbook for systematic reviews of diagnostic test accuracy, Version 1.0. The Cochrane Collaboration: Oxford, UK, 2010; Available at: (last accessed 12 December 2011).
  • 16
    Dwamena B. Midas: stata module for meta-analytical integration of diagnostic test accuracy studies. Statistical Software Components S456880, Boston College Department of Economics, 2007. Available at: (last accessed 12 December 2011).
  • 17
    Acosta J, Catalan M, del Palacio-Perez-Medel A et al. A prospective comparison of galactomannan in bronchoalveolar lavage fluid for the diagnosis of pulmonary invasive aspergillosis in medical patients under intensive care: comparison with the diagnostic performance of galactomannan and of (1-->3)-beta-d-glucan chromogenic assay in serum samples. Clin Microbiol Infect2011; 17: 10531060.
  • 18
    Damiani C, Le Gal S, Lejeune D et al. Serum (1->3)-beta-d-glucan levels in primary infection and pulmonary colonization with pneumocystis jirovecii. J Clin Microbiol2011; 49: 20002002.
  • 19
    de Boer MG, Gelinck LB, van Zelst BD et al. Beta-d-glucan and s-adenosylmethionine serum levels for the diagnosis of pneumocystis pneumonia in hiv-negative patients: a prospective study. J Infect2010; 62: 93100.
  • 20
    Held J, Koch M, Reischl U, Danner T, Serr A. Serum (1-->3)-beta-d-glucan measurement as early indicator for pneumocystis jirovecii pneumonia and evaluation of its prognostic value. Clin Microbiol Infect2010; 17: 595602.
  • 21
    Desmet S, Van Wijngaerden E, Maertens J et al. Serum (1-3)-beta-d-glucan as a tool for diagnosis of pneumocystis jirovecii pneumonia in patients with human immunodeficiency virus infection or hematological malignancy. J Clin Microbiol2009; 47: 38713874.
  • 22
    Koo S, Bryar JM, Page JH, Baden LR, Marty FM. Diagnostic performance of the (1-->3)-beta-d-glucan assay for invasive fungal disease. Clin Infect Dis2009; 49: 16501659.
  • 23
    Nakamura H, Tateyama M, Tasato D et al. Clinical utility of serum beta-d-glucan and kl-6 levels in pneumocystis jirovecii pneumonia. Intern Med2009; 48: 195202.
  • 24
    Watanabe T, Yasuoka A, Tanuma J et al. Serum (1-->3) beta-d-glucan as a noninvasive adjunct marker for the diagnosis of pneumocystis pneumonia in patients with aids. Clin Infect Dis2009; 49: 11281131.
  • 25
    Obayashi T, Negishi K, Suzuki T, Funata N. Reappraisal of the serum (1-->3)-beta-d-glucan assay for the diagnosis of invasive fungal infections--a study based on autopsy cases from 6 years. Clin Infect Dis2008; 46: 18641870.
  • 26
    Persat F, Ranque S, Derouin F, Michel-Nguyen A, Picot S, Sulahian A. Contribution of the (1-->3)-beta-d-glucan assay for diagnosis of invasive fungal infections. J Clin Microbiol2008; 46: 10091013.
  • 27
    Tasaka S, Hasegawa N, Kobayashi S et al. Serum indicators for the diagnosis of pneumocystis pneumonia. Chest2007; 131: 11731180.
  • 28
    Iikuni N, Kitahama M, Ohta S, Okamoto H, Kamatani N, Nishinarita M. Evaluation of pneumocystis pneumonia infection risk factors in patients with connective tissue disease. Mod Rheumatol2006; 16: 282288.
  • 29
    Mori T, Matsumura M. Clinical evaluation of diagnostic methods using plasma and/or serum for three mycoses: aspergillosis, candidosis, and pneumocystosis. Nippon Ishinkin Gakkai Zasshi1999; 40: 223230.
  • 30
    Yasuoka A, Tachikawa N, Shimada K, Kimura S, Oka S. (1-->3) beta-d-glucan as a quantitative serological marker for pneumocystis carinii pneumonia. Clin Diagn Lab Immunol1996; 3: 197199.
  • 31
    Karageorgopoulos DE, Vouloumanou EK, Ntziora F, Michalopoulos A, Rafailidis PI, Falagas ME. Β-d-glucan assay for the diagnosis of invasive fungal infections: a meta-analysis. Clin Infect Dis2011; 52: 750770.
  • 32
    Fujii T, Nakamura T, Iwamoto A. Pneumocystis pneumonia in patients with hiv infection: clinical manifestations, laboratory findings, and radiological features. J Infect Chemother2007; 13: 17.
  • 33
    Marty FM, Koo S, Bryar J, Baden LR. (1->3)beta-d-glucan assay positivity in patients with pneumocystis (carinii) jiroveci pneumonia. Ann Intern Med2007; 147: 7072.
  • 34
    Shimizu A, Oka H, Matsuda T, Ozaki S. (1-->3)-beta-d glucan is a diagnostic and negative prognostic marker for pneumocystis carinii pneumonia in patients with connective tissue disease. Clin Exp Rheumatol2005; 23: 678680.
  • 35
    Sax PE, Komarow L, Finkelman MA et al. Blood (1->3)-beta-d-glucan as a diagnostic test for hiv-related pneumocystis jirovecii pneumonia. Clin Infect Dis2011; 53: 197202.
  • 36
    Digby J, Kalbfleisch J, Glenn A, Larsen A, Browder W, Williams D. Serum glucan levels are not specific for presence of fungal infections in intensive care unit patients. Clin Diagn Lab Immunol2003; 10: 882885.
  • 37
    Ellis M, Al-Ramadi B, Finkelman M et al. Assessment of the clinical utility of serial beta-d-glucan concentrations in patients with persistent neutropenic fever. J Med Microbiol2008; 57: 287295.
  • 38
    Marty FM, Koo S. Role of (1-->3)-beta-d-glucan in the diagnosis of invasive aspergillosis. Med Mycol2009; 47 (Suppl 1): S233S240.
  • 39
    Acosta J, Catalan M, Del Palacio-Perez-Medel A et al. Prospective study in critically ill non-neutropenic patients: diagnostic potential of (1,3)-beta-d-glucan assay and circulating galactomannan for the diagnosis of invasive fungal disease. Eur J Clin Microbiol Infect Dis2011; [Epub ahead of print].
  • 40
    Racil Z, Kocmanova I, Lengerova M et al. Difficulties in using 1,3-{beta}-d-glucan as the screening test for the early diagnosis of invasive fungal infections in patients with haematological malignancies--high frequency of false-positive results and their analysis. J Med Microbiol2010; 59: 10161022.
  • 41
    Cuenca-Estrella M, Bassetti M, Lass-Florl C, Racil Z, Richardson M, Rogers TR. Detection and investigation of invasive mould disease. J Antimicrob Chemother2011; 66 (Suppl 1): i15i24.
  • 42
    Finkelman MA. pneumocystis jirovecii infection: cell wall (1[RIGHTWARDS ARROW]3)-β-d-glucan biology and diagnostic utility. Crit Rev Microbiol2010; 36: 271281.
  • 43
    Calderon EJ, Gutierrez-Rivero S, Durand-Joly I, Dei-Cas E. Pneumocystis infection in humans: diagnosis and treatment. Expert Rev Anti Infect Ther2010; 8: 683701.
  • 44
    Pisculli ML, Sax PE. Use of a serum beta-glucan assay for diagnosis of hiv-related pneumocystis jiroveci pneumonia in patients with negative microscopic examination results. Clin Infect Dis2008; 46: 19281930.
  • 45
    Leigh TR, Kangro HO, Gazzard BG, Jeffries DJ, Collins JV. DNA amplification by the polymerase chain reaction to detect sub-clinical pneumocystis carinii colonization in hiv-positive and hiv-negative male homosexuals with and without respiratory symptoms. Respir Med1993; 87: 525529.
  • 46
    Shimizu Y, Sunaga N, Dobashi K et al. Serum markers in interstitial pneumonia with and without pneumocystis jirovecii colonization: a prospective study. BMC Infect Dis2009; 9: 47.
  • 47
    Odabasi Z, Mattiuzzi G, Estey E et al. Beta-d-glucan as a diagnostic adjunct for invasive fungal infections: validation, cutoff development, and performance in patients with acute myelogenous leukemia and myelodysplastic syndrome. Clin Infect Dis2004; 39: 199205.
  • 48
    Leeflang MM, Deeks JJ, Gatsonis C, Bossuyt PM. Systematic reviews of diagnostic test accuracy. Ann Intern Med2008; 149: 889897.